GenOMICC: Genetics of Susceptibility and Mortality in Critical Care
Principal Investigator: Prof. Anil Hormis Sponsor: NHS Lothian / University of Edinburgh GenOMICC is a, open, collaborative, global community of doctors and scientists trying to understand and treat critical illness. Our partners have been recruiting patients since 2016 to study emerging infections (SARS/MERS/Flu), sepsis, and other forms of critical illness. It is the largest study of its kind anywhere in the world. Open to Associate PI scheme |
MARCH trial (Mucoactives in Acute Respiratory failure: Carbocisteine and Hypertonic saline)
Principal Investigator: Prof. Anil Hormis Sponsor: Queen's University Belfast / Belfast Health and Social Care Trust A 2×2 factorial, randomised, controlled, open-label, Phase 3, pragmatic, clinical and cost effectiveness trial with internal pilot, to determine whether mucoactives (carbocisteine and hypertonic saline) in critically ill patients with acute respiratory failure (ARF) reduce duration of mechanical ventilation Open to Associate PI scheme |
UK-ROX: Evaluating the Clinical and Cost-Effectiveness of a Conservative Approach to Oxygen Therapy for Invasively Ventilated Adults in Intensive Care
Principal Investigator: Prof. Anil Hormis Associate PI: Dr Jake McCormick Sponsor: Intensive Care National Audit & Research Centre 'Around 184,000 critically ill adults are admitted to intensive care units (ICUs) each year in the UK. Over 30% of these will require help from a breathing machine (called a ventilator), often in combination with additional oxygen. As such, oxygen is the most common therapy used to treat patients admitted to an ICU, who require help from a ventilator. Despite this, we do not know how much oxygen to give to patients in order to optimise their recovery. ... Our aim is to find out whether keeping oxygen saturations at lower levels (conservative oxygen therapy) is better than the higher level that is currently being used in the NHS to treat patients in ICU needing help from a ventilator.' Open to Associate PI scheme |
PRECISiON Study
Principal Investigator: Prof. Anil Hormis Sponsor: Portsmouth University Hospital NHS Trust/Portsmouth Technology Trial Unit An observational study of host biomarker signatures that predict the onset of sepsis in patients with lower respiratory tract infections including COVID-19: Utility in managing patients at risk of multi-organ failure. Open to Associate PI scheme |